The answer to this question depends on how this emerging clinical research model challenges the standard expectations ethics has of clinical trials and whether ethics itself has to formulate a new critique to account for the novel aspects of phase 0 trials. In addition, providing an answer is a
No takes yet. Share an insight, caveat, or question.
T. Patrick Hill (2007) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: